The efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum ?-lactamase producing Enterobacteriaceae.

Link to article at PubMed

The efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum ?-lactamase producing Enterobacteriaceae.

Antimicrob Agents Chemother. 2012 Jan 30;

Authors: Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon I, Hayakawa K, Odaliz AL, Chopra T, Munoz-Price S, Carmeli Y, Kaye K

Abstract
Ertapenem is active against ESBLs but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to lack of therapeutic data for ertapenem in treatment of ESBL bloodstream infections (BSI), group 2 carbapenems (e.g. imipenem or meropenem) are often preferred for treatment of ESBLs, although their anti-pseudomonal activity is unnecessary. From 2005-2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and group 2 carbapenems (mortality rates 6% and 18%, p=0.18).

PMID: 22290982 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.